Symbols / EPRX Stock $7.16 -1.24% Eupraxia Pharmaceuticals Inc.

Healthcare • Biotechnology • Canada • NCM
EPRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. James A. Helliwell FRCPC, M.D.
Exch · Country NCM · Canada
Market Cap 440.36M
Enterprise Value 388.10M
Income -41.11M
Sales —
FCF (ttm) -16.30M
Book/sh 1.01
Cash/sh 1.31
Employees 49
Insider 10d —
IPO Apr 05, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -11.14
PEG —
P/S —
P/B 7.11
P/C —
EV/EBITDA -10.14
EV/Sales —
Quick Ratio 14.44
Current Ratio 15.12
Debt/Eq 0.19
LT Debt/Eq —
EPS (ttm) -1.03
EPS next Y -0.64
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-03-12
ROA -39.67%
ROE -68.76%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 61.50M
Shs Float 45.63M
Insider Own 14.80%
Instit Own 30.98%
Short Float —
Short Ratio 12.47
Short Interest 2.54M
52W High 9.32
vs 52W High -23.18%
52W Low 3.67
vs 52W Low 95.25%
Beta 1.42
Impl. Vol. —
Rel Volume 0.76
Avg Volume 219.63K
Volume 167.71K
Target (mean) $14.39
Tgt Median $14.00
Tgt Low $11.00
Tgt High $19.00
# Analysts 7
Recom Strong_buy
Prev Close $7.25
Price $7.16
Change -1.24%
About

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.39
Mean price target
2. Current target
$7.16
Latest analyst target
3. DCF / Fair value
$-4.77
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.16
Low
$11.00
High
$19.00
Mean
$14.39

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 reit HC Wainwright & Co. Buy → Buy $11
2026-03-23 init William Blair — → Outperform —
2026-03-17 main HC Wainwright & Co. Buy → Buy $11
2026-01-15 main Cantor Fitzgerald Overweight → Overweight $19
2026-01-09 reit HC Wainwright & Co. Buy → Buy $12
2025-08-20 reit HC Wainwright & Co. Buy → Buy $12
2025-07-24 init Cantor Fitzgerald — → Overweight $11
2025-06-26 init HC Wainwright & Co. — → Buy $12
2024-11-14 init Rodman & Renshaw — → Buy $9
News
RSS: Latest EPRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-27 Helliwell (James Allen) Director of Issuer — 30,000 $2.16 $64,800
2026-03-27 Pimstone (Simon Neil) Director of Issuer — 2,500 $6.76 $16,897
2026-03-27 Pimstone (Simon Neil) Director of Issuer — 2,000 $6.77 $13,532
2026-03-27 Pimstone (Simon Neil) Director of Issuer — 2,000 $6.80 $13,590
2026-03-27 Pimstone (Simon Neil) Director of Issuer — 3,000 $6.84 $20,514
2026-03-27 Pimstone (Simon Neil) Director of Issuer — 2,500 $6.87 $17,167
2026-03-18 Freedman (Joseph Stuart) Director of Issuer — 1,700 $7.94 $13,496
2026-03-18 Freedman (Joseph Stuart) Director of Issuer — 4,200 $7.80 $32,772
2026-03-18 Freedman (Joseph Stuart) Director of Issuer — 3,874 $7.40 $28,683
2026-03-18 Freedman (Joseph Stuart) Director of Issuer — 1,800 $7.76 $13,959
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
38.43
+42.33%
27.00
-3.03%
27.85
+58.07%
17.62
Research And Development
21.33
+32.67%
16.08
-21.04%
20.36
+49.40%
13.63
Selling General And Administration
17.10
+56.56%
10.92
+45.96%
7.48
+87.68%
3.99
General And Administrative Expense
17.10
+56.56%
10.92
+45.96%
7.48
+87.68%
3.99
Salaries And Wages
10.34
+98.39%
5.21
+76.42%
2.96
+9.71%
2.69
Other Gand A
5.77
+21.39%
4.76
+14.29%
4.16
+344.56%
0.94
Other Operating Expenses
—
—
—
0.16
Total Expenses
38.43
+42.33%
27.00
-3.03%
27.85
+58.07%
17.62
Operating Income
-38.43
-42.33%
-27.00
+3.03%
-27.85
-58.07%
-17.62
EBITDA
-38.35
-53.60%
-24.97
+9.55%
-27.60
-54.56%
-17.86
Normalized EBITDA
-36.78
-43.29%
-25.67
+4.31%
-26.83
-57.47%
-17.04
Reconciled Depreciation
0.24
+38.43%
0.17
+10.41%
0.16
+5.16%
0.15
EBIT
-38.59
-53.49%
-25.14
+9.44%
-27.76
-54.15%
-18.01
Total Unusual Items
-1.57
-322.19%
0.70
+190.87%
-0.78
+5.73%
-0.82
Total Unusual Items Excluding Goodwill
-1.57
-322.19%
0.70
+190.87%
-0.78
+5.73%
-0.82
Special Income Charges
-0.00
+99.24%
-0.34
-6853.59%
-0.00
+26.99%
-0.01
Other Special Charges
—
0.36
—
—
Net Income
-38.58
-51.26%
-25.50
+9.63%
-28.22
-52.63%
-18.49
Pretax Income
-38.59
-49.89%
-25.74
+11.02%
-28.93
-52.34%
-18.99
Net Non Operating Interest Income Expense
1.41
+153.88%
0.56
+281.11%
-0.31
+44.25%
-0.55
Interest Expense Non Operating
0.00
-100.00%
0.60
-48.42%
1.17
+19.06%
0.98
Net Interest Income
1.41
+153.88%
0.56
+281.11%
-0.31
+44.25%
-0.55
Interest Expense
0.00
-100.00%
0.60
-48.42%
1.17
+19.06%
0.98
Interest Income Non Operating
1.41
+21.77%
1.16
+34.41%
0.86
+99.85%
0.43
Interest Income
1.41
+21.77%
1.16
+34.41%
0.86
+99.85%
0.43
Other Income Expense
-1.57
-322.19%
0.70
+190.87%
-0.78
+5.73%
-0.82
Other Non Operating Income Expenses
—
—
—
—
Gain On Sale Of Security
-1.56
-250.05%
1.04
+235.18%
-0.77
+5.56%
-0.82
Tax Provision
0.02
+958.26%
0.00
-95.05%
0.04
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-0.31
0.00
Net Income Including Noncontrolling Interests
-38.61
-49.96%
-25.74
+11.12%
-28.97
-52.53%
-18.99
Net Income From Continuing Operation Net Minority Interest
-38.58
-51.26%
-25.50
+9.63%
-28.22
-52.63%
-18.49
Net Income From Continuing And Discontinued Operation
-38.58
-51.26%
-25.50
+9.63%
-28.22
-52.63%
-18.49
Net Income Continuous Operations
-38.61
-49.96%
-25.74
+11.12%
-28.97
-52.53%
-18.99
Minority Interests
0.03
-87.80%
0.24
-67.53%
0.75
+48.70%
0.50
Normalized Income
-37.01
-41.23%
-26.21
+5.58%
-27.76
-57.10%
-17.67
Net Income Common Stockholders
-38.58
-51.26%
-25.50
+9.63%
-28.22
-52.63%
-18.49
Diluted EPS
-1.03
-35.53%
-0.76
+35.04%
-1.17
-21.87%
-0.96
Basic EPS
-1.03
-35.53%
-0.76
+35.04%
-1.17
-21.87%
-0.96
Basic Average Shares
39.96
+17.76%
33.93
+40.52%
24.15
+25.21%
19.29
Diluted Average Shares
39.96
+17.76%
33.93
+40.52%
24.15
+25.21%
19.29
Diluted NI Availto Com Stockholders
-38.58
-51.26%
-25.50
+9.63%
-28.22
-52.63%
-18.49
Depreciation Amortization Depletion Income Statement
—
—
—
0.14
Depreciation And Amortization In Income Statement
—
—
—
0.14
Depreciation Income Statement
—
—
—
0.14
Gain On Sale Of PPE
-0.00
-113.77%
0.02
+484.05%
-0.00
+26.99%
-0.01
Insurance And Claims
0.99
+3.25%
0.95
+159.72%
0.37
+2.71%
0.36
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
86.15
+146.55%
34.94
+72.42%
20.27
+5.98%
19.12
Current Assets
85.10
+147.12%
34.44
+73.90%
19.80
+6.53%
18.59
Cash Cash Equivalents And Short Term Investments
80.56
+143.38%
33.10
+71.14%
19.34
+5.90%
18.26
Cash And Cash Equivalents
80.56
+143.38%
33.10
+71.14%
19.34
+5.90%
18.26
Cash Financial
80.56
+143.38%
33.10
+71.14%
19.34
—
Other Short Term Investments
—
—
—
0.00
Receivables
0.67
+194.59%
0.23
+20.07%
0.19
+112.46%
0.09
Other Receivables
—
—
—
0.01
Taxes Receivable
0.67
+194.59%
0.23
+20.07%
0.19
+151.39%
0.08
Prepaid Assets
3.86
+248.92%
1.11
+308.74%
0.27
+14.75%
0.24
Total Non Current Assets
1.05
+107.93%
0.51
+9.18%
0.46
-13.14%
0.53
Net PPE
0.99
+132.31%
0.42
-6.87%
0.46
-14.04%
0.53
Gross PPE
1.63
+84.41%
0.88
+3.55%
0.85
+3.73%
0.82
Accumulated Depreciation
-0.64
-40.13%
-0.46
-15.48%
-0.40
-35.95%
-0.29
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
—
0.09
Machinery Furniture Equipment
0.23
+67.75%
0.14
-9.12%
0.15
+12.15%
0.14
Other Properties
1.27
+102.55%
0.63
+9.57%
0.57
+1.98%
0.56
Leases
0.13
+8.00%
0.12
-8.08%
0.13
+2.40%
0.13
Non Current Prepaid Assets
0.06
-20.34%
0.08
+1069.77%
0.01
+177.05%
0.00
Total Liabilities Net Minority Interest
5.70
+83.80%
3.10
-83.98%
19.37
+62.61%
11.91
Current Liabilities
5.63
+81.35%
3.10
-83.98%
19.37
+533.47%
3.06
Payables And Accrued Expenses
5.55
+83.06%
3.03
-62.40%
8.06
+233.85%
2.42
Payables
1.52
+1.73%
1.49
-70.34%
5.04
—
Other Payable
1.52
+1.62%
1.49
-70.12%
5.00
—
Current Accrued Expenses
4.03
+162.09%
1.54
-49.20%
3.03
+25.32%
2.42
Pensionand Other Post Retirement Benefit Plans Current
—
1.49
+74.00%
0.86
+67.28%
0.51
Total Tax Payable
0.00
0.00
-100.00%
0.04
0.00
Current Debt And Capital Lease Obligation
0.08
+9.17%
0.07
-99.31%
10.45
+7951.11%
0.13
Current Debt
—
—
10.40
+12993.65%
0.08
Other Current Borrowings
—
—
10.40
+12993.65%
0.08
Current Capital Lease Obligation
0.08
+9.17%
0.07
+34.78%
0.05
+5.78%
0.05
Current Deferred Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
0.08
0.00
0.00
-100.00%
8.86
Long Term Debt And Capital Lease Obligation
0.08
0.00
0.00
-100.00%
8.86
Long Term Debt
—
—
—
8.80
Long Term Capital Lease Obligation
0.08
0.00
0.00
-100.00%
0.05
Stockholders Equity
82.04
+145.60%
33.40
+1407.30%
2.22
-71.54%
7.79
Common Stock Equity
52.30
+2977.41%
1.70
-23.31%
2.22
-71.54%
7.79
Capital Stock
225.15
+52.06%
148.07
+59.36%
92.91
+30.86%
71.00
Common Stock
195.41
+67.93%
116.36
+25.23%
92.91
+30.86%
71.00
Preferred Stock
29.74
-6.20%
31.71
0.00
—
Share Issued
51.94
+45.73%
35.64
+30.64%
27.28
+26.35%
21.59
Ordinary Shares Number
51.94
+45.73%
35.64
+30.64%
27.28
+26.35%
21.59
Additional Paid In Capital
28.52
+39.10%
20.50
+17.10%
17.51
+3.92%
16.85
Retained Earnings
-169.58
-29.45%
-131.00
-24.17%
-105.50
-36.52%
-77.28
Gains Losses Not Affecting Retained Earnings
-2.04
+50.87%
-4.16
-53.72%
-2.71
+2.86%
-2.79
Minority Interest
-1.60
-1.88%
-1.57
-18.28%
-1.32
-128.78%
-0.58
Other Equity Adjustments
-2.04
+50.87%
-4.16
-53.72%
-2.71
+2.86%
-2.79
Total Equity Gross Minority Interest
80.45
+152.67%
31.84
+3468.09%
0.89
-87.62%
7.21
Total Capitalization
82.04
+145.60%
33.40
+1407.30%
2.22
-86.64%
16.59
Working Capital
79.47
+153.63%
31.33
+7200.82%
0.43
-97.24%
15.53
Invested Capital
52.30
+2977.41%
1.70
-86.53%
12.61
-24.33%
16.67
Total Debt
0.15
+114.81%
0.07
-99.31%
10.45
+16.32%
8.99
Capital Lease Obligations
0.15
+114.81%
0.07
+34.78%
0.05
-47.58%
0.10
Net Tangible Assets
82.04
+145.60%
33.40
+1407.30%
2.22
-71.54%
7.79
Tangible Book Value
52.30
+2977.41%
1.70
-23.31%
2.22
-71.54%
7.79
Derivative Product Liabilities
—
—
—
—
Dueto Related Parties Current
—
—
—
—
Preferred Stock Equity
29.74
-6.20%
31.71
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-28.55
+4.81%
-29.99
-44.56%
-20.75
-44.14%
-14.40
Cash Flow From Continuing Operating Activities
-28.55
+4.81%
-29.99
-44.56%
-20.75
-44.14%
-14.40
Net Income From Continuing Operations
-38.61
-49.96%
-25.74
+11.12%
-28.97
-52.53%
-18.99
Depreciation Amortization Depletion
0.24
+38.43%
0.17
+10.41%
0.16
+5.16%
0.15
Depreciation
0.24
+38.43%
0.17
+10.41%
0.16
+5.16%
0.15
Depreciation And Amortization
0.24
+38.43%
0.17
+10.41%
0.16
+5.16%
0.15
Other Non Cash Items
-0.08
-142.15%
0.18
-64.96%
0.52
-21.05%
0.66
Stock Based Compensation
9.04
+180.38%
3.22
+128.25%
1.41
-1.50%
1.43
Operating Gains Losses
1.57
+1040.96%
0.14
+330.04%
-0.06
+72.44%
-0.22
Gain Loss On Investment Securities
—
—
—
—
Unrealized Gain Loss On Investment Securities
0.00
+100.00%
-1.20
-243.50%
0.84
-20.79%
1.06
Net Foreign Currency Exchange Gain Loss
1.57
+903.28%
0.16
+341.59%
-0.06
+71.12%
-0.22
Gain Loss On Sale Of PPE
0.00
+113.77%
-0.02
-484.05%
0.00
-29.55%
0.01
Change In Working Capital
-0.71
+89.45%
-6.76
-226.40%
5.35
+253.35%
1.51
Change In Receivables
-0.43
-325.54%
-0.10
+2.24%
-0.10
-145.00%
0.23
Change In Prepaid Assets
-2.64
-178.66%
-0.95
-674.63%
-0.12
-206.40%
-0.04
Change In Payables And Accrued Expense
2.36
+141.31%
-5.71
-202.46%
5.58
+321.28%
1.32
Change In Payable
2.36
+141.31%
-5.71
-202.46%
5.58
+321.28%
1.32
Change In Account Payable
2.36
+430.22%
-0.71
-223.70%
0.58
-56.35%
1.32
Investing Cash Flow
-0.59
-683.60%
-0.08
-2.43%
-0.07
-100.75%
9.83
Cash Flow From Continuing Investing Activities
-0.59
-683.60%
-0.08
-2.43%
-0.07
-100.75%
9.83
Net PPE Purchase And Sale
-0.59
-683.60%
-0.08
-2.43%
-0.07
+68.82%
-0.24
Purchase Of PPE
-0.59
-465.06%
-0.10
-42.04%
-0.07
+68.85%
-0.24
Sale Of PPE
0.00
-100.00%
0.03
0.00
-100.00%
0.00
Capital Expenditure
-0.59
-465.06%
-0.10
-42.04%
-0.07
+68.85%
-0.24
Net Investment Purchase And Sale
—
—
0.00
-100.00%
10.07
Purchase Of Investment
—
—
0.00
+100.00%
-3.27
Sale Of Investment
—
—
0.00
-100.00%
13.34
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
76.06
+66.12%
45.78
+117.20%
21.08
+95.16%
10.80
Cash Flow From Continuing Financing Activities
76.06
+66.12%
45.78
+117.20%
21.08
+95.16%
10.80
Net Issuance Payments Of Debt
0.00
+100.00%
-9.14
-11402.20%
-0.08
+44.16%
-0.14
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
0.00
+100.00%
-9.14
-11402.20%
-0.08
+44.16%
-0.14
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
0.00
+100.00%
-0.06
+21.14%
-0.08
+44.16%
-0.14
Net Long Term Debt Issuance
0.00
+100.00%
-0.06
+21.14%
-0.08
+44.16%
-0.14
Short Term Debt Payments
0.00
+100.00%
-9.07
0.00
—
Net Short Term Debt Issuance
0.00
+100.00%
-9.07
0.00
—
Net Common Stock Issuance
73.89
+35.43%
54.56
+243.43%
15.89
+49.36%
10.64
Proceeds From Stock Option Exercised
2.17
+496.99%
0.36
-93.11%
5.27
+1618.51%
0.31
Changes In Cash
46.92
+198.56%
15.71
+6015.33%
0.26
-95.88%
6.24
Effect Of Exchange Rate Changes
0.54
+127.87%
-1.96
-338.01%
0.82
+261.89%
-0.51
Beginning Cash Position
33.10
+71.14%
19.34
+5.90%
18.26
+45.75%
12.53
End Cash Position
80.56
+143.38%
33.10
+71.14%
19.34
+5.90%
18.26
Free Cash Flow
-29.14
+3.18%
-30.10
-44.55%
-20.82
-42.32%
-14.63
Interest Paid Supplemental Data
0.00
-100.00%
0.39
-34.16%
0.60
—
Common Stock Issuance
73.89
+35.43%
54.56
+243.43%
15.89
+49.36%
10.64
Issuance Of Capital Stock
73.89
+35.43%
54.56
+243.43%
15.89
+49.36%
10.64
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category